Lecanemab shows potential as Alzheimer's treatment

Having trouble viewing this message? You may view it as a web page. You may also view e-news archives. To prevent mailbox filters from deleting your Alzheimer's Association email communications, please add alzheimers_enews@alz.org to your address book. November 30, 2022   24/7 Helpline: 800.272.3900 Lecanemab shows potential as Alzheimer’s treatment The drug lecanemab shows potential as an Alzheimer’s disease treatment, according to new Phase 3 trial results. Lecanemab is an experimental dementia drug that appears to slow the progression of cognitive decline. The Alzheimer’s Association is encouraged by these results and calls for the U.S. Food and Drug Administration’s accelerated approval of lecanemab. Respite care may help Alzheimer’s caregivers recharge Respite care provides caregivers a temporary break while a person living with Alzheimer's continues to receive care in a safe environment. Using respite services can support and strengthen your ability to be a caregiver. Help fight Alzheimer's Give Now Get Involved Your Local Community Iowa Chapter   People living with Alzheimer's can take action to help others People living with Alzheimer's have a unique opportunity to turn their experience into inspiration for others. Their voice and actions are powerful tools that can help to raise concern and awareness and empower others. Create a free, customized action plan with Alzheimer's Navigator.   More Resources:  Stages of Alzheimer's  |  Behaviors  |  Coping Strategies  |  Care Training My Preferences: Unsubscribe To stop receiving our weekly e-newsletter, simply unsubscribe.   Subscribe Was this e-newsletter forwarded to you? Subscribe to get it weekly. The Alzheimer's Association leads the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Alzheimer's Association Home Office 225 N. Michigan Ave., Fl. 17, Chicago, IL 60601 © 2022 Alzheimer's Association. All rights reserved. www.alz.org | 800.272.3900.